Daraxonrasib (RMC-6236): Selectivity & Specificity
Daraxonrasib (RMC-6236) is a potent pan-RAS inhibitor targeting all RAS isoforms. (RAS/KRAS/HRAS/NRAS)
Jump to:
- Daraxonrasib (RMC-6236) Mechanism of Action: RAS Inhibition in Pancreatic Cancer Cell Research
- Daraxonrasib (RMC-6236) Working Concentration | Cell Culture | Treatment
- Daraxonrasib (RMC-6236) Solubility in DMSO
- Daraxonrasib (RMC-6236) Storage & Stability
- Daraxonrasib (RMC-6236) Combination Database
- Daraxonrasib (RMC-6236) Molecular Weight | Chemical Structure | Stock Solution
- Daraxonrasib (RMC-6236) IC50 for Cell-based and Cell-free Assays
- Daraxonrasib (RMC-6236) Sigma (SML4213)? Try a better option.
- Daraxonrasib (RMC-6236) MCE (HY-148439)? Try a better option.
- Daraxonrasib (RMC-6236) Cayman (41982)? Try a better option.
- Daraxonrasib (RMC-6236) Abmole (M40832)? Try a better option.
- Daraxonrasib (RMC-6236) SDS｜MSDS
- Daraxonrasib (RMC-6236) in Pancreatic Ductal Adenocarcinoma (PDAC)
- Daraxonrasib (RMC-6236) in Non-Small Cell Lung Cancer (NSCLC)
- Daraxonrasib (RMC-6236) in Colorectal Cancer (CRC)